Navigation Links
Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
Date:5/4/2010

ST. LOUIS, May 4 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today updates progress on a global multi-center clinical study on ventricular tachycardia treatment outcomes by using the company's proprietary Niobe® Magnetic Navigation System.

Ventricular tachycardia (VT) is a life-threatening arrhythmia because it may lead to ventricular fibrillation, asystole, and sudden death.  VT is one of the most challenging arrhythmias facing electrophysiologists due to complex anatomy, the sensitive nature of ventricular tissue, and potentially lethal outcomes.  Catheter ablation of VT, one of the fastest growing EP procedures globally, requires the delivery of robust lesions for clinical success.  

The prospective multi-center clinical effort, named "Study
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Stereotaxis Installs First System in Taiwan
2. Stereotaxis System Procedure Featured on NBCs The TODAY Show
3. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
4. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
6. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
7. Stereotaxis Announces Public Offering of Common Stock
8. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
9. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
10. Stryker Updates Expected 2009 Results and Provides 2010 Outlook
11. Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...
... 2012  Vision-Sciences, Inc. (NASDAQ:  VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...
Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2Henry Schein's Chairman and CEO Addresses the World Economic Forum 3Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2
(Date:5/21/2013)... have long been known for their health benefits, ... therapies like anti-cancer drugs are delivered to specific ... uncovered how to create nanoparticles using natural lipids ... use them as drug delivery vehicles. UofL scientists ... their team today (May 21, 2013), published their ...
(Date:5/21/2013)... Residents in St. Petersburg, FL have a ... Dr. David Sherberg, DMD, has joined Coast Dental Pasadena, ... provides preventive, restorative and cosmetic dentistry to patients age ... provide a wide variety of services including ... crowns, bridges, dentures, dental implant restorations, veneers, laser therapy, ...
(Date:5/21/2013)... May 21, 2013 Vyopta Incorporated, ... automation applications for video collaboration, today announced the ... index evaluates key performance metrics related to quality, ... immediate, aggregated indicator of the performance of their ... Vyopta vAnalytics™ application, the vRating™ delivers high level ...
(Date:5/21/2013)... TheBeautyPlace.com helps brides to breathe a ... Big Day Kit including all the essentials a glowing ... on their Wedding Day. , TheBeautyPlace.com features Wedding Day ... their Wedding Day. Flowers blooming and warmer weather indicates ... season. From Memorial Day to October, brides to be ...
(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...
Breaking Medicine News(10 mins):Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 2Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 3Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3
... May 16 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... that the Company,will present at the following conferences:, ... cities in China. David Gao, ... scheduled to present on May 19, 2008, ...
... University of Texas M. D. Anderson Cancer Center have ... shutting down their energy source and hastening cell starvation. ... fellow from the Children,s Cancer Hospital at M. D. ... with mTOR inhibitor, rapamycin, induced more than 90 percent ...
... Available, RADNOR, Pa., May 16 This ... Older Pennsylvanians Month, Feeling Blue,Suicide Prevention Council (SPC) ... a public service announcement. The public service,announcement developed ... awareness,to the public health problem of depression and ...
... Conn., May 16 Tao Formulations announces ... Relief Formula, at the Internal,Medicine 2008 conference ... culmination of years of research to develop ... menopausal symptoms., Company founder and CEO, ...
... 2 Diabetes and High LDL- ... Cholesterol ... ACE/AACE Road Maps, PARSIPPANY, N.J., May 16 Daiichi Sankyo, Inc. (DSI),announced ... combination with metformin- or,sulfonylurea- based therapy, significantly lowers blood glucose (as,measured by A1C) ...
... number of women undergoing mastectomy (total breast removal) for ... years at Mayo Clinic in Rochester. The increase follows ... Researchers say the reasons for this increase are unclear. ... who underwent diagnostic magnetic resonance imaging (MRI) prior to ...
Cached Medicine News:Health News:BMP Sunstone Announces Participation in May Investor Conferences 2Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly 2Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
... 5.0 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: